Bio/Pharma News

Poseida Therapeutics and Astellas to Develop Novel Allogeneic Cell Therapies

May 07, 2024

The two companies will combine their cell therapy platforms to develop convertibleCAR programs targeting solid tumors.

N4 Pharma and SRI to Collaborate on Intracellular Delivery to Specific Target Cells

April 26, 2024

The collaboration will combine N4’s nanoparticle delivery system with SRI’s molecular guidance system.

How New Regulations Are Impacting Pharmaceutical Manufacturing Facility Design

April 19, 2024

New regulations, including those put forth by Annex 1, require many pharmaceutical manufacturers to rethink their facility designs to promote compliance.

FDA Approves New Antibiotic to Treat Three Different Bacterial Infections

April 05, 2024

Zevtera has been approved to treat three types of bacterial infections and has been granted Priority Review and Fast Track and Qualified Infectious Disease Product designations.

Genmab Expands ADC Pipeline with $1.8 Billion Acquisition of ProfoundBio

April 04, 2024

Genmab's acquisition of ProfoundBio will boost its clinical and preclinical pipeline of ADCs for targeted cancer treatment.

J&J's Nipocalimab for FNAIT Gets on Fast Track for Approval

March 30, 2024

FDA granted fast track designation to nipocalimab, which J&J is developing for helping alloimmunized pregnant adults treat FNAIT, a rare disease that poses risk to the fetus or newborn.

Dr. Reddy’s Partners with Sanofi Healthcare India to Distribute Vaccines

March 29, 2024

Dr. Reddy’s has gained exclusive rights to promote and distribute Sanofi’s vaccines in India.

AstraZeneca Gains FDA Nod for Ultomiris, a Treatment for Managing NMOSD

March 29, 2024

FDA has approved AstraZeneca's Ultomiris, marking the first and only long-acting C5 complement inhibitor for patients with NMOSD.

AbbVie Gains Landos Biopharma and Full FDA Approval for ADC Product

March 28, 2024

The Landos acquisition adds a lead asset in autoimmune and inflammatory disease to AbbVie's portfolio, while the company's ADC, ELAHERE, gets full FDA approval.

AstraZeneca to Acquire Amolyt Pharma in Deal Worth Potentially $1.05 Billion

March 22, 2024

AstraZeneca’s acquisition of Amolyt Pharma includes eneboparatide, a Phase III therapeutic peptide for the treatment of hypoparathyroidism.